

Prophylactic Antibody Therapy

High risk patients who have had a high risk exposure and meet antibody therapy requirements (below), are able to receive prophylactic antibody infusions as long as they are referred within 5 days and receive therapy within 7 days.

❖ Requirements for prophylaxis infusion:

- Inadequate immune protection against COVID-19 which is defined by either of the following:
 - Not fully vaccinated against COVID-19
 - Not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination, such as persons with immunocompromising conditions including those taking immunosuppressive medications
- Meets at least one of the following criteria:
 - Age ≥ 65 years
 - BMI ≥ 25 kg/m²
 - Pregnancy
 - Chronic kidney disease
 - Diabetes
 - Immunosuppressive disease or immunosuppressive treatment
 - Cardiovascular disease (including congenital heart disease) or hypertension
 - Chronic lung diseases (including chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
 - Sickle cell disease
 - Neurodevelopmental disorders or other conditions that confer medical complexity
 - Medical-related technological dependence (including tracheostomy, gastrostomy)



Provider Workflow

1. Patient contacts clinic stating that they had a high risk exposure

- High risk exposure is defined by either of the following:
 - Close contact (within 6 feet of someone for a cumulative total of 15 minutes or more over a 24-hour period, or for inpatient roommates of patients for any duration who have been determined to be actively infectious per hospital epidemiology) with someone who has COVID-19. Persons with COVID-19 are considered infectious for 48 hours prior to initial symptom onset or first positive test (whichever is earlier).
 - High-risk exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example: nursing homes, prisons)

2. If patient meets high risk criteria (above), order a COVID test to be completed **that day** from SmartSet

a. ILI: RESPIRATORY ILLNESS CLINIC ORDERS orderset [7386]

FOLLOW-UP - ILI RESPIRATORY CLINIC (Symptomatic and High Risk Exposed Testing - 2 Visits - MyChart Scheduled)

FOLLOW-UP - ILI RESPIRATORY CLINIC (Asymptomatic High Risk Exposed Testing - PAC Scheduled)

Exposure Testing

FOLLOW-UP - ILI RESPIRATORY CLINIC: COVID-19 Testing Only; No; Yes
Reason for Visit: COVID-19 Testing Only
Outpatient with symptoms of COVID-19? No
Patient was a close contact (spending more than 15 minutes within 6 feet) of a person with lab confirmed COVID-19 infection; sample collection is more than 48 hours after first exposure and less than 14 days after last exposure. Yes
Interpreter Needed (specify language)? No
Auto Release, Sign

COVID-19 HIGH RISK EXPOSURE ■
Expires: 10/7/2021, Nasopharyngeal swab
This test is approved for patients who have had a high-risk exposure to COVID-19. Acknowledge
If patient has not been exposed but needs asymptomatic screening (pre-procedure, pre-travel, pre-transplant, neonate, prior to discharge, or admission to congregate settings), please exit and order- COVID-19 ASYMPTOMATIC SCREEN BY PCR; RESTRICTED-LAB8978: Acknowledge
Auto Release, Sign

3. If patient's COVID test is negative, start a telephone encounter and put in order:

PHARMACY REFERRAL FOR MONOCLONAL ANTIBODY PROPHYLAXIS [INS313]

PHARMACY REFERRAL FOR MONOCLONAL ANTIBODY PROPHYLAXIS ✓ Accept ✗ Cancel

1 Has patient experienced a high risk exposure within the last 5 days?

1 Is patient inadequately immunoprotected against COVID-19 (i.e. not fully vaccinated or not expected to mount full response to vaccine)?

1 Does patient have documented negative SARS-CoV-2 test in past 24 hours?

1 Does patient meet criteria for high risk of progression to severe disease (see high-risk list below)?

Process Inst.: Patients who are considered high-risk:
- Age =65 years
- BMI => >25 kg/m2
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (including chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders or other conditions that confer medical complexity
- Medical-related technological dependence (including tracheostomy, gastrostomy)

Reference Links: 1. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab 2. Casirivimab-Imdevimab Fact Sheet for Patients and Caregivers

Comments: [+ Add Comments \(F6\)](#)

1 Next Required Link Order ✓ Accept ✗ Cancel

4. The referral goes to Pharmacy to contact patient to get scheduled for their Antibody prophylaxis therapy.